United Therapeutics Corp. (NASDAQ:UTHR) Director Tommy G. Thompson sold 1,291 shares of the stock in a transaction dated Monday, September 26th. The shares were sold at an average price of $125.57, for a total transaction of $162,110.87. Following the transaction, the director now directly owns 1,291 shares of the company’s stock, valued at approximately $162,110.87. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink.
United Therapeutics Corp. (NASDAQ:UTHR) opened at 115.02 on Friday. The company’s 50-day moving average is $123.71 and its 200 day moving average is $116.00. United Therapeutics Corp. has a one year low of $97.52 and a one year high of $164.04. The stock has a market capitalization of $5.00 billion, a price-to-earnings ratio of 5.56 and a beta of 1.46.
United Therapeutics Corp. (NASDAQ:UTHR) last posted its earnings results on Thursday, July 28th. The biotechnology company reported $4.55 earnings per share for the quarter, beating the consensus estimate of $3.22 by $1.33. The company had revenue of $412.60 million for the quarter, compared to analyst estimates of $395.15 million. United Therapeutics Corp. had a net margin of 64.26% and a return on equity of 49.30%. United Therapeutics Corp.’s revenue was up 18.8% on a year-over-year basis. During the same period in the previous year, the business posted $2.55 EPS. Equities analysts expect that United Therapeutics Corp. will post $15.82 EPS for the current year.
UTHR has been the topic of a number of recent analyst reports. Wedbush reissued an “outperform” rating and issued a $229.00 price objective on shares of United Therapeutics Corp. in a research report on Thursday, July 28th. HC Wainwright reissued a “hold” rating on shares of United Therapeutics Corp. in a research report on Friday, July 29th. Zacks Investment Research raised shares of United Therapeutics Corp. from a “hold” rating to a “buy” rating and set a $137.00 price objective on the stock in a research report on Wednesday. Argus reissued a “hold” rating on shares of United Therapeutics Corp. in a research report on Tuesday, August 23rd. Finally, Jefferies Group reissued a “hold” rating and issued a $120.00 price objective on shares of United Therapeutics Corp. in a research report on Friday, July 29th. Eight research analysts have rated the stock with a hold rating and four have given a buy rating to the company. The stock has an average rating of “Hold” and a consensus price target of $137.09.
A number of institutional investors have recently bought and sold shares of UTHR. GSA Capital Partners LLP raised its position in United Therapeutics Corp. by 4.0% in the second quarter. GSA Capital Partners LLP now owns 32,696 shares of the biotechnology company’s stock valued at $3,463,000 after buying an additional 1,267 shares during the last quarter. Bessemer Group Inc. purchased a new position in United Therapeutics Corp. during the first quarter valued at $947,000. NN Investment Partners Holdings N.V. purchased a new position in United Therapeutics Corp. during the first quarter valued at $9,601,000. Acrospire Investment Management LLC purchased a new position in United Therapeutics Corp. during the first quarter valued at $267,000. Finally, JPMorgan Chase & Co. raised its position in United Therapeutics Corp. by 45.3% in the first quarter. JPMorgan Chase & Co. now owns 260,328 shares of the biotechnology company’s stock valued at $29,009,000 after buying an additional 81,110 shares during the last quarter.
United Therapeutics Corp. Company Profile
United Therapeutics Corporation is a biotechnology company. The Company is focused on the development and commercialization of products for the treatment of chronic and life-threatening conditions. Its therapeutic products and product candidates include Prostacyclin Analogues, Phosphodiesterase Type 5 (PDE-5) Inhibitor and Monoclonal Antibody (MAb).
Receive News & Ratings for United Therapeutics Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics Corp. and related companies with MarketBeat.com's FREE daily email newsletter.